By Ruth Adebayo
In a groundbreaking advancement for global HIV prevention, the World Health Organization (WHO) has officially recommended the use of lenacapavir (LEN) a long-acting injectable drug administered just twice a year as a safe and effective method to prevent HIV infection.
The new guidance marks a significant milestone, as LEN becomes the first twice-yearly injectable pre-exposure prophylaxis (PrEP) option, it offers a discreet, convenient, and highly effective alternative to daily oral medication, particularly for individuals facing challenges such as stigma, inconsistent access to healthcare, or daily adherence difficulties.
The WHO emphasized the importance of this option for vulnerable groups, including sex workers, LGBTQ+ communities, and people living in underserved or high-risk regions.
In addition to the drug recommendation, WHO announced simplified HIV testing options, allowing people to access services at community clinics, pharmacies, and online platforms all designed to reduce stigma and make prevention easier and more private.
Dr. Meg Doherty, Director of WHO’s Department of Global HIV, Hepatitis and STI Programmes, stated “We have the tools and the knowledge to end AIDS as a public health problem. What we need now is bold implementation of these recommendations, grounded in equity and powered by communities.”
Experts say this innovation could dramatically accelerate global efforts to reduce new infections and empower communities worldwide in the fight against AIDS.
